A program that improves both survival and quality of life is worth offering
En el congreso anual de la Sociedad Americana de Oncología Clínica en Chicago, tres estudios emergentes están reencuadrando una verdad que la medicina ha tardado en asumir: el peso corporal no es un problema paralelo al cáncer, sino una dimensión activa de él. Investigadores italianos demuestran que programas estructurados de dieta mediterránea, caminata diaria y vitamina D reducen la recurrencia del cáncer de mama y mejoran la calidad de vida, mientras que los fármacos GLP-1, conocidos por tratar la diabetes y la obesidad, muestran potencial para frenar la metástasis. Lo que se debate en Chicago no es solo ciencia clínica, sino una pregunta más antigua: ¿cuánto tiempo puede la medicina tratar la enfermedad sin tratar al ser humano que la porta?
- Tres de cada cuatro pacientes con cáncer de mama tienen sobrepeso u obesidad, una realidad que agrava los síntomas, reduce la respuesta al tratamiento y eleva el riesgo de muerte, pero que durante décadas recibió solo consejos sin apoyo estructurado.
- El programa BWEL, aplicado a 1.500 pacientes, demostró que una intervención sencilla y de bajo coste —dieta mediterránea, caminata diaria, vitamina D— no solo reduce el riesgo de recurrencia, sino que devuelve energía, movilidad y vida social a quienes atraviesan el cáncer.
- Los fármacos GLP-1 como semaglutida y tirzepatida, ya masivamente prescritos para diabetes y obesidad, están siendo investigados ahora por su posible capacidad de frenar la metástasis y prevenir tumores asociados a la obesidad, abriendo un frente terapéutico aún poco comprendido.
- La oncología rara vez ofrece intervenciones que mejoren simultáneamente la supervivencia y la calidad de vida; estos estudios sugieren que el manejo del peso podría ser una de ellas, transformando lo que hoy es una recomendación vaga en un componente estándar del tratamiento oncológico.
La Sociedad Americana de Oncología Clínica se reúne este año en Chicago con una pregunta incómoda sobre la mesa: ¿por qué la medicina oncológica ha tardado tanto en tratar el peso como parte del tratamiento del cáncer? Tres estudios presentados en el congreso ofrecen respuestas concretas y, en algunos casos, sorprendentemente accesibles.
El más llamativo proviene de investigadores italianos y se llama BWEL. Durante el programa, 1.500 pacientes con cáncer de mama siguieron la dieta mediterránea, caminaron a diario y tomaron vitamina D. Los resultados fueron dobles: mejoraron metabólicamente y redujeron su riesgo de recurrencia, pero también vivieron mejor. Tenían más energía, se movían con mayor facilidad y participaban más en su vida cotidiana. Marcin Chwistek, jefe de oncología del Fox Chase Cancer Center, señaló que durante años los médicos dijeron a sus pacientes que perdieran peso sin ofrecerles ningún apoyo real para lograrlo. BWEL cambió esa conversación.
El contexto es difícil de ignorar: tres de cada cuatro pacientes diagnosticadas con cáncer de mama tienen sobrepeso u obesidad. El exceso de peso no llega después del cáncer ni al margen de él; lo moldea desde dentro, agravando los síntomas, debilitando la respuesta a la terapia y elevando el riesgo de recaída y muerte.
Una segunda línea de investigación apunta a los fármacos GLP-1 —semaglutida, tirzepatida— que nacieron para tratar la diabetes y se han extendido como tratamiento para la obesidad. Los primeros datos sugieren que podrían prevenir ciertos cánceres vinculados al exceso de peso, especialmente el colorrectal, y que quizás sean capaces de frenar la metástasis en pacientes que ya tienen cáncer. Es un territorio aún poco explorado, pero los estudios presentados en Chicago comienzan a iluminarlo.
Lo que emerge de todo esto es un cambio de perspectiva: el manejo del peso no es una recomendación que el oncólogo lanza al final de la consulta. Es, o podría ser, una parte activa y medible del tratamiento desde el primer día. Para millones de pacientes, eso no significa solo vivir más tiempo, sino vivir mejor mientras lo hacen.
The American Society of Clinical Oncology is about to convene for its annual congress in Chicago, and the research being presented this year is turning attention toward something oncologists have long suspected but struggled to act on: the weight a patient carries matters profoundly to their cancer outcomes. Three early studies being unveiled focus on the Mediterranean diet, structured weight management, and a newer class of diabetes drugs called GLP-1 agonists—all showing measurable effects on cancer progression and survival.
Italian researchers have completed a program they call BWEL, and the results are straightforward enough that they seem almost obvious in retrospect. Patients with breast cancer who followed the Mediterranean diet, walked daily, and took vitamin D supplements not only lost weight but experienced something more clinically significant: their metabolic syndrome improved, their risk of cancer recurrence dropped, and their physical functioning and fatigue levels improved in ways that could be measured. The program cost little and posed no safety concerns. It worked on a population of 1,500 people—a substantial cohort.
What makes this finding noteworthy is not the weight loss itself. Marcin Chwistek, chief of oncology at Fox Chase Cancer Center and a member of ASCO's leadership, put it plainly: for years, doctors have told overweight and obese cancer patients to lose weight without offering them any structured support to do so. BWEL changed that conversation. The program did not just improve survival statistics—it improved how patients actually lived. They had more energy, moved more easily, engaged more in their social lives. "A program that improves both survival and quality of life at the same time is something worth offering," Chwistek said. That distinction matters. Oncology is not usually a field where you get to improve both metrics simultaneously.
The context makes the finding urgent. Three out of every four patients diagnosed with breast cancer are overweight or obese. Excess weight is not incidental to their cancer experience—it shapes it. Patients carrying extra weight experience worse symptoms during treatment. Their bodies respond less well to therapy. They face higher risks of recurrence and death. The weight is not a separate problem to address after cancer treatment ends; it is woven into the cancer itself.
A second line of research is now examining GLP-1 agonists—drugs like semaglutide and tirzepatide that were developed for diabetes but have become widely used for weight loss. Early work suggests these medications may prevent certain cancers, particularly colorectal cancer and other tumors linked to obesity. But what researchers are now investigating is their effect on patients who already have cancer, specifically on metastasis—the spread of cancer from its original site to distant organs. The drugs are increasingly prescribed, yet their effects on cancer progression remain poorly understood. These new studies are beginning to fill that gap.
What is emerging from this research is a shift in how oncology might approach the patient sitting across from the desk. Weight management is not a lifestyle recommendation to pursue after cancer treatment concludes. It is an active part of cancer care itself, something that can be measured, supported, and integrated into the treatment plan from the beginning. For millions of patients, particularly those with breast cancer, this represents a concrete intervention that improves not just how long they live but how well they live while doing so.
Citas Notables
We've spent years asking overweight and obese cancer patients to lose weight without giving them structured support. This program changed that conversation by improving both survival and quality of life.— Marcin Chwistek, chief of oncology at Fox Chase Cancer Center
La Conversación del Hearth Otra perspectiva de la historia
Why has weight management taken so long to become standard cancer care if the connection is this clear?
Because oncologists have historically treated cancer and weight as separate domains. You see a cancer patient, you treat the cancer. The weight is their problem to solve. But the research is showing the weight is not separate—it's part of the cancer biology itself.
So the Mediterranean diet and vitamin D aren't magic. They're just... good interventions that happen to work?
Exactly. They're not exotic. They're accessible, affordable, and they address the underlying metabolic dysfunction that obesity creates. The novelty is not the intervention—it's treating it as oncology, not lifestyle advice.
What about the GLP-1 drugs? Those are expensive and they're everywhere now. Are they going to become standard cancer treatment?
That's the question being asked right now. They show promise in preventing certain cancers and potentially slowing metastasis. But we don't yet know the full picture of how they work in people who already have cancer, or what the long-term effects are.
Three out of four breast cancer patients are overweight. That's a staggering number.
It is. And it means that for most women diagnosed with breast cancer, weight is not an edge case—it's the norm. If you can improve outcomes for that population, you're changing outcomes for the majority of patients.
The Chwistek quote mentions quality of life alongside survival. That seems like it shouldn't be remarkable, but it is.
It is, because in cancer care, you often have to choose. You can extend life but the treatment is brutal. Here, the intervention improves both. That's rare enough to be worth paying attention to.